Mankind Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2113.1, up 2.84% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 25467.85. The Sensex is at 82264.76, up 0.05%. Mankind Pharma Ltd has gained around 0.9% in last one month.

Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 5.38% in last one month and is currently quoting at 22632.05, up 1.45% on the day. The volume in the stock stood at 3.22 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2126.3, up 2.78% on the day. Mankind Pharma Ltd is down 7.89% in last one year as compared to a 12.96% jump in NIFTY and a 13.66% jump in the Nifty Pharma index.

The PE of the stock is 47.98 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Net profit of Mankind Pharma rose 7.50% to Rs 408.75 crore in the quarter ended December 2025 as against Rs 380.23 crore during the previous quarter ended December 2024. Sales rose 11.52% to Rs 3567.20 crore in the quarter ended December 2025 as against Rs 3198.79 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Securities in F&O Ban:

Sammaan Capital shares are banned from F&O trading on 04 February 2026.

New SME Listing:

Accretion Nutraveda is set to list on the SME Platform today. The issue opened for bidding 28 January 2026 and it closed 30 January 2025. The price band of the IPO was fixed between Rs 122 to Rs 129 per share. The issue was subscribed 1.77 times.

Msafe Equipment set to debut on the SME platform today. The issue opened for bidding on 28 January 2026 and it closed on 30 January 2025. The price band of the IPO was fixed between Rs 116 to Rs 123 per share. The issue was subscribed 153.98 times.

Kanishk Aluminium India will list on SME platform today. The issue opened for bidding on 28 January 2026 and it closed 30 January 2026. The price band of the IPO was fixed at Rs 73 per share. The minimum order quantity is 1,600 equity shares.

Result Today:

Archean Chemical Industries, Apollo Tyres, Aptus Value Housing Finance India, Aurionpro Solutions, Automotive Axles, Avalon Technologies, Bajaj Finserv, Bajaj Holdings & Investment, Carysil, CCL Products (India), Century Plyboards (India), Cera Sanitaryware, Cummins India, Devyani International, Emami, Emcure Pharmaceuticals, Eureka Forbes, Force Motors, Gallantt Ispat, Greenply Industries, Hexaware Technologies, Inventurus Knowledge Solutions, Jain Irrigation Systems, Jaiprakash Power Ventures, JSW Cement, Jubilant Ingrevia, Kalpataru Projects International, Lloyds Engineering Works, Global Health, Metropolis Healthcare, NHPC, Parag Milk Foods, Apeejay Surrendra Park Hotels, Pokarna, Quality Power Electrical Equipments, Redington, RITES, Rane (Madras), Keystone Realtors, Saatvik Green Energy, Sammaan Capital, Shipping Corporation of India Land and Assets, Tata Power Company, Transport Corporation of India, TeamLease Services, Tube Investments of India, Timken India, Tamilnad Mercantile Bank, Trent, Welspun Enterprises, Westlife Foodworld, Wonderla Holidays and Xpro India will announce their quarterly earnings today.

Stocks to Watch:

Bajaj Finance reported 6.33% decline in consolidated net profit to Rs 3,977.85 crore in Q3 FY26 compared with Rs 4,246.54 crore in Q3 FY25. Total revenue from operations jumped 17.63% YoY to Rs 21,213.89 crore in Q3 FY26.

Mankind Pharma reported a 7.6% year-on-year increase in consolidated net profit to Rs 409 crore, driven by an 11.5% rise in revenue from operations to Rs 3,567 crore in Q3 FY26, compared with Q3 FY25.

Godrej Agrovet posted a 3% year-on-year growth in consolidated net profit to Rs 115 crore, while revenue increased 11% to Rs 2,718 crore in Q3 FY26 over Q3 FY25.

Rubucon Research reported 91.2% jump in consolidated net profit to Rs 72.8 crore on 51.7% increase in revenue from operations to Rs 475.5 crore in Q3 FY26 over Q3 FY25.

Aditya Birla Capital?s consolidated net profit jumped 33.48% to Rs 945.02 crore on 27.4% increase in revenue from operations to Rs 11952.09 crore in Q3 FY36 over Q2 FY25.

Powered by Capital Market - Live News

Mankind Pharma announced that ICRA has assigned the rating ICRA AA+; Stable / ICRA A1+ for debt facilities of the company including non-convertible debentures. The rating on commercial paper of ICRA A1+ has been withdrawn.

Powered by Capital Market - Live News